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Abstract
The abundant, nuclear-retained, metastasis-associated lung
adenocarcinoma transcript 1 (MALAT1) has been associated with a
poorly differentiated and aggressive phenotype of mammary carci-
nomas. This long non-coding RNA (lncRNA) localizes to nuclear
speckles, where it interacts with a subset of splicing factors and
modulates their activity. In this study, we demonstrate that onco-
genic splicing factor SRSF1 bridges MALAT1 to mutant p53 and ID4
proteins in breast cancer cells. Mutant p53 and ID4 delocalize
MALAT1 from nuclear speckles and favor its association with chro-
matin. This enables aberrant recruitment of MALAT1 on VEGFA
pre-mRNA and modulation of VEGFA isoforms expression. Interest-
ingly, VEGFA-dependent expression signatures associate with ID4
expression specifically in basal-like breast cancers carrying TP53
mutations. Our results highlight a key role for MALAT1 in control
of VEGFA isoforms expression in breast cancer cells expressing
gain-of-function mutant p53 and ID4 proteins.
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Introduction
The eukaryotic genome harbors a large number of non-coding RNAs,
which include small and long non-coding RNAs (lncRNAs). The
nuclear-retained Metastasis-Associated Lung Adenocarcinoma Tran-
script 1 (MALAT1), also known as Nuclear-Enriched Abundant Tran-
script 2 (NEAT2), is one of the most abundant and highly conserved
lncRNAs and is overexpressed in several cancers; its elevated
expression has been associated with hyperproliferation, metastasis,
and poor prognosis [1–5]. 30-end processing of MALAT1 has been
shown to yield a tRNA-like cytoplasmic RNA [6,7]. MALAT1 local-
izes to nuclear speckles, a subnuclear domain suggested to coordi-
nate RNA polymerase II transcription, pre-mRNA splicing, and
mRNA export [8–11]. MALAT1 interacts with several pre-mRNA
splicing factors [12–14] including serine–arginine dipeptide-rich SR-
family splicing factors such as SRSF1 (also known as ASF/SF2),
SC35 (SRSF2), and SRSF3. This lncRNA has been shown to induce
the expression of cell cycle genes and to control alternative splicing
of pre-mRNAs by modulating the intranuclear distribution of SR
splicing factors [15,16]. Interestingly, knockdown of MALAT1 has
no impact on the formation, size, and number of nuclear speckles,
whereas it does result in a decreased nuclear speckle association of
several pre-mRNA splicing factors, including SRSF1 [10,17,18].
SRSF1, a prototype member of the SR protein family mostly
recruited to exonic splicing enhancers (ESEs), is a multifunctional
RNA-binding protein with roles in pre-mRNA constitutive and alter-
native splicing, mRNA export, and mRNA translation; it was identi-
fied as an oncogene due to its transforming capacity in vitro and
in vivo [19–23]. Activity of SRSF1 is crucial for alternative splicing
control of the terminal exon of the VEGFA gene, a major determinant
in tumor neoangiogenesis [24]. Two families of VEGFA isoforms are
indeed generated by alternate splice-site selection in the gene’s
terminal exon, exon 8. Proximal splice-site selection (PSS) in exon 8
results in pro-angiogenic VEGFAxxx isoforms (xxx is the number of
amino acids), whereas distal splice-site selection (DSS) results in
anti-angiogenic VEGFAxxxb isoforms [25–29]. SRSF1 has been
shown to favor PSS selection in exon 8 during VEGFA pre-mRNA
splicing [26]. The anti-angiogenic VEGFAxxxb isoform is downregu-
lated in several epithelial cancer types and in other pathologies asso-
ciated with abnormal neovascularization [30–32]. VEGFA165b
inhibits VEGFR2 signaling by inducing differential phosphorylation,
and it can be used to block angiogenesis in in vivo models of
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tumorigenesis. Recombinant human VEGFA165b (rhVEGFA165b)
treatment in vivo also has a growth-inhibitory effect in nude mice
xenograft models of various tumors [33–36]. VEGFA165 and
VEGFA121 are among the most abundant pro-angiogenic VEGFA
isoforms in cancer cells and have been very recently shown to exert
opposite effects on the growth and invasion of tumor cells in vivo
[37].
We previously characterized a molecular network whereby gain-
of-function mutant p53 (mtp53) proteins are responsible for induc-
tion of the ID4 protein in breast cancer [38]. Mtp53 proteins are
peculiarly characterized by a prolonged half-life compared with that
of the wt-p53 protein, and many mtp53 proteins show the inability
to recognize wt-p53 DNA-binding sites. Many of these mtp53
proteins presenting high levels of expression in cancer cells have
been also demonstrated to have various oncogenic properties [39–
41]; many mtp53 proteins have indeed been shown to present gain-
of-function (GOF) activity, positively contributing to tumorigenesis
in vivo and conferring increased aggressiveness phenotype to cell
lines in vitro [42].
ID4 protein expression is enriched in breast cancer tissues exhibit-
ing p53 overexpression (indicating the presence of a TP53 gene
mutation). The net biological output of the transcriptional activation
of the ID4 gene by mutant p53 is the increase in the angiogenic
potential of mutant p53-carrying tumor cells. Despite the absence of
an RNA-binding domain in its protein sequence, ID4 protein has
been shown to interact, probably indirectly, with the mRNAs of pro-
angiogenic factors and to increase their stability and rate of transla-
tion [38,43]. Accordingly, high ID4 protein expression is associated
with high microvessel density in breast cancer [38]. Several studies
have shown that high ID4 mRNA and protein expressions are associ-
ated with the highly aggressive basal-like subtype of breast cancer
(BLBC), characterized by a substantially high incidence of TP53 gene
mutations (nearly 80%), expression of basal cytokeratins, and
absence of estrogen, progesterone, and ERBB2 receptors [44–47].
High ID4 expression in BLBC has been related to poor disease-free
and overall survival [47,48]. A recent study showed that ID4 is a key
regulator of mammary stem cell self-renewal and marks a subset of
BLBC with a putative mammary basal cell origin [48].
The present study aimed to identify mediators of ID4-associated
pro-angiogenic activity in breast cancer. We report the identification
of a quaternary ribonucleoprotein (RNP) complex comprising the
MALAT1 lncRNA and the SRSF1 oncogenic splicing factor, as well as
mutant p53 and ID4 proteins. This RNP complex is recruited on
VEGFA pre-mRNA, where it inhibits the synthesis of anti-angiogenic
VEGFAxxxb isoforms. Accordingly, the depletion of MALAT1 or of any
of the protein components of this RNP complex leads to a reduction
in the angiogenic potential of breast cancer cells. Moreover, High ID4
expression is associated with an enriched VEGFA-activity expression
signature specifically in mutant p53-carrying basal-like breast cancer.
Results
Splicing factor SRSF1 stabilizes the binding of ID4 and mutant
p53 proteins to lncRNA MALAT1 in breast cancer cells
We previously showed that mutant p53 proteins induce ID4 expres-
sion in breast cancer cells. ID4 protein is able to bind to the mRNAs
encoding pro-angiogenic cytokines and favors their translation,
resulting in enhanced neoangiogenesis [38,43].
To identify additional mediators of angiogenesis controlled by
ID4, we performed a RIP-chip analysis (Ribonucleoprotein
ImmunoPrecipitation followed by microarray analysis) in MDA-MB-
468 breast cancer cells, which led to the identification of a panel of
RNAs bound by ID4 (Appendix Tables S1 and S2). Interestingly,
among ID4-targeted RNAs, we identified MALAT1, a long non-
coding RNA (lncRNA) that has been reported to modulate activity of
serine/arginine-rich (SR) proteins in the nucleus. SR proteins and
heterogeneous nuclear ribonucleoproteins (hnRNPs) are the major
classes of splicing factors that select splice sites for recognition by
the spliceosome through binding to intronic or exonic splice
elements. The expression of specific isoforms of VEGFA, a major
player in tumor angiogenesis, depends on the SR-family protein
SRSF1, whose activity is in turn controlled by MALAT1; for this
reason, we explored the possibility that ID4 controls VEGFA expres-
sion by modulating MALAT1 and SRSF1 activities.
Using native lysates from different breast cancer cell lines, we
confirmed by RIP assays that ID4 binds to MALAT1 (Fig 1A and
B, and Appendix Fig S1A). Interaction between ID4 protein and
MALAT1 lncRNA was also confirmed by RIP assay in MDA-MB-
468 cells overexpressing HA-tagged ID4 protein (Appendix Fig
S1B). Interestingly, we observed that also the mutant p53
(mtp53) proteins p53R175H (endogenously expressed in SKBR3
cells) and p53R273H (endogenously expressed in MDA-MB-468
and OVCAR-3 cells) are able to bind to this lncRNA (Figs 1C
and EV1A). Combined immunofluorescence for p53 and RNA
FISH for MALAT1 showed colocalization of mtp53 protein and
MALAT1 in MDA-MB-468 and SKBR3 cells (Figs 1D and E, and
EV1B).
On the contrary, immunoprecipitation of endogenous wild-type
p53 in MCF7 breast cancer and in breast-derived MCF10A cells, in
which wt-p53 was stabilized or not by a DNA-damaging agent,
evidenced no binding to MALAT1 (Fig EV1C–E). Of note, also ID4
protein did not bind to MALAT1 in these wt-p53 cell contexts
(Fig EV1E). Interestingly, staining of MALAT1 RNA by FISH assay
evidenced different patterns of intranuclear localization in MCF7 and
MDA-MB-468 cells, with MCF7 cells showing MALAT1 mainly local-
ized in speckles and MDA-MB-468 showing also a diffused localiza-
tion of MALAT1, beyond the speckles (Fig EV1F).
We decided to investigate whether ID4 and mtp53 bind to
MALAT1 directly or other RNA-binding proteins mediate their bind-
ing to MALAT1. To this end, we performed RIP experiments using
lysates from cells crosslinked with formaldehyde, which leads to
protein:protein and protein:RNA covalent links, or with UV light,
which links covalently interacting protein:RNA avoiding protein:
protein crosslinks. As shown in Fig 1A and C, ID4 and p53 proteins
bind to MALAT1 only in cells crosslinked with formaldehyde, indi-
cating these as indirect interactions.
One of the best-characterized MALAT1-dependent factors is the
oncogenic splicing factor SRSF1, which has been shown to be upreg-
ulated in breast cancer and to promote transformation of mammary
cells [19,20]. To explore whether SRSF1 is responsible for the bind-
ing of ID4 and mutant p53 proteins to MALAT1, we first performed
RIP experiments in MDA-MB-468 cells to determine whether SRSF1
protein actually interacts with MALAT1 in our experimental setting.
SRSF1 has been demonstrated to interact directly with MALAT1
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[13]. Consistent with these published data [10,13], we observed a
strong enrichment specifically for MALAT1 lncRNA, and not for
NEAT1 lncRNA (not interacting with SRSF1 in previous reports
[10]), among the RNAs immunoprecipitated with anti-SRSF1 anti-
body compared to IgG negative control, in native lysates as well as
in lysates from cells crosslinked with formaldehyde and UV light
(Fig 1F).
Of note, depletion of SRSF1 expression (Figs 1G and EV1G) in
MDA-MB-468 cells significantly decreased the binding of ID4 and
mutant p53 proteins to MALAT1, as assessed by RIP assay (Fig 1H).
Mutant p53 and ID4 interact with SRSF1 in a
MALAT1-dependent manner
We next explored whether ID4 and mutant p53 proteins interact with
splicing factor SRSF1. Using a proximity ligation assay (PLA), we
first assessed that both ID4 and mutant p53 interact with SRSF1 in
MDA-MB-468 and SKBR3 cells (Fig 2A and B, si-SCR; Fig EV2A). An
interaction between ID4 and mutant p53 was also detected (Fig 2C,
si-SCR; Fig EV2A). Importantly, depletion of MALAT1 (Fig 2D and
E) by RNA interference significantly reduced the number of ID4-
SRSF1 and mutant p53-SRSF1 interactions (Figs 2A and B, and
EV2A–C), indicating that these are RNA-dependent interactions.
In contrast, the mutant p53-ID4 interaction was not affected by
MALAT1 interference (Figs 2C and EV2A–C) or by SRSF1 interfer-
ence (Fig EV2D and E).
As a control for the specificity of the mutant p53-SRSF1 interac-
tion, we analyzed this complex by PLA assay in parental MDA-MB-
468, as well as in the same cell strain with stable depletion of
endogenous mutant p53 expression (sh-p53). Analysis of p53 levels
in these stable cell lines is shown in Appendix Fig S1C. As shown in
Fig 2F and G, the mutant p53-SRSF1 interaction was strongly
reduced upon mutant p53 depletion (sh-p53).
The interaction between mutant p53 and SRSF1 proteins was also
detected in Co-ImmunoPrecipitation (Co-IP) experiments using p53-
null H1299 cells transfected with a mutant p53R273H expression
vector or an empty vector as negative control (Fig 2H). Immunopre-
cipitation of ID4 protein followed by Western blot of p53 and SRSF1
in the same cells showed the existence of ID4-p53R273H and ID4-
SRSF1 complexes (Fig 2I). Co-IP experiments in SKBR3 cells
evidenced the mutant p53R175H-SRSF1 complex, which was
impaired when lysate was treated with RNase A or when cells were
depleted of SRSF1 expression (Fig 2J).
Mutant p53 and ID4 stabilize binding of SRSF1 to MALAT1
We next raised the question of whether mutant p53 and ID4
expression influences the binding of SRSF1 to MALAT1. To this
end, MDA-MB-468 cells were transfected with si-RNAs directed to
p53 or ID4 mRNAs (Fig 3A and B), and cell extracts were used to
immunoprecipitate SRSF1. Importantly, mutant p53 or ID4 deple-
tion reduced SRSF1 binding to MALAT1 (Fig 3C). It has been
◀ Figure 1. ID4 and mutant p53 proteins bind to MALAT1 lncRNA in SRSF1-dependent manner.A–C RIP (Ribonucleoprotein ImmunoPrecipitation) assays performed in SKBR3 and MDA-MB-468 breast cancer cells using antibodies directed to ID4 or p53. IgG was
used as negative control. Native lysates or lysates from cells crosslinked with formaldehyde (F.A.) or UV light were employed. RT–qPCR of MALAT1 RNA and control
mRNAs (GAPDH, RPL19) is shown. Relative enrichment represents enrichment of each transcript in ID4-IP or p53-IP over control IgG-IP sample.
D Fluorescence high-resolution images of fixed cells, labeled with DAPI (cell nuclei), Alexa Fluor 488 (p53 protein), and Quasar 570 (MALAT1 RNA). Merged images of
Alexa Fluor 488 and Quasar 570 signals are shown. Scale bars, 10 lm.
E Pearson’s correlation coefficient R, Manders correlation coefficient M2 (tM2), and Li intensity correlation quotient ICQ (Li) were considered to estimate
colocalization between p53 protein and MALAT1 RNA from combined immunofluorescence–RNA FISH assays in the indicated cell lines.
F RIP assays performed in MDA-MB-468 cells using an antibody directed to SRSF1 (A96, Santa Cruz). MALAT1 and NEAT1 (negative control) RNA abundance was
evaluated by RT–qPCR.
G, H RIP assays of ID4 and p53 performed in MDA-MB-468 cells depleted or not of SRSF1 expression using two siRNAs. SRSF1, ID4, p53 proteins, and MALAT1 RNA levels
following siRNA transfection are shown in (G).
Data information: Data are presented as mean  SEM. *P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0005 (two-tailed Student’s t-test). Results from at least three biological replicates
are shown.
Source data are available online for this figure.
▸Figure 2. SRSF1 interacts with mutant p53 and ID4 proteins in a MALAT1-dependent manner.A–C Proximity ligation assays (PLAs) of SRSF1-mutant p53 (A), SRSF1-ID4 (B), and mutant p53-ID4 (C) interactions in MDA-MB-468 cells depleted (si-MALAT1) or not
(si-SCR) of MALAT1 RNA expression using two different siRNAs. Box plots represent the number of interactions detected per nucleus.
D, E Western blot (D) and RT–qPCR (E) analysis of MDA-MB-468 cells depleted of MALAT1 RNA expression using two different siRNAs.
F, G PLA of SRSF1-p53 interaction in parental MDA-MB-468 cells (indicated as R273H) as well as in cells stably depleted of endogenous mutant p53R273H expression
(indicated as sh-p53). Immunofluorescence (F) represents p53 staining, DAPI (cell nuclei), PLA signals (SRSF1-p53 interactions), and merged signals DAPI/PLA.
Box plot (G) represents the number of SRSF1-p53 interactions detected per nucleus. Scale bars, 0.01 mm.
H, I H1299 cells transfected with mutant p53R273H vector or an empty vector as control were used to evaluate SRSF1-p53 interaction (H) by immunoprecipitation of
SRSF1 (and IgG as control) followed by Western blot of p53, ID4-p53R273H (I), and ID4-SRSF1 (I) interactions by immunoprecipitation of ID4 followed by Western
blot of p53 and SRSF1, respectively.
J SRSF1-p53 interaction evaluated in SKBR3 cell lysate, treated or not with RNase A, by immunoprecipitation of SRSF1 (and IgG as control) followed by Western blot
of p53.
Data information: *P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001 (two-tailed Student’s t-test). n.s: not significant. Results from at least three biological replicates are shown.
(A–C, G) The horizontal line represents the median, the box represents the inter-quartile range and 10–90th percentile interval is shown in whiskers. The black circles
represent outliers. (E) Data are presented as mean  SEM.
Source data are available online for this figure.
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reported that MALAT1 RNA contains several SRSF1-binding sites
that are distributed along the whole sequence of the transcript
[10,13]. RIP assays for SRSF1, performed in cells subjected to
crosslinking and sonication, followed by analysis of enrichments
on 14 regions spanning the whole MALAT1 RNA, evidenced a
major site of enrichment in the 50 half of MALAT1 (Fig 3D). Addi-
tional regions significantly enriched were also identified along
MALAT1 RNA. Depletion of ID4 caused reduction in SRSF1 bind-
ing to MALAT1 in all the enriched regions (Fig 3D), while its
interaction with other well-established target pre-mRNAs was not
significantly affected (Fig EV3A). Interestingly, ID4 depletion also
impaired binding of SRSF1 protein to mutant p53, as assessed by
PLA assay (Figs 3E and EV3B).
As reciprocal approach, we performed a ChIRP assay (Chromatin
Isolation by RNA Purification) [49]. Specifically, MALAT1-asso-
ciated proteins and RNAs were recovered by using a series of
biotinylated oligonucleotides spanning the whole MALAT1
sequence, in control MDA-MB-468 cells (si-SCR), as well as in ID4-
depleted (si-ID4) and mutant p53-depleted (si-p53) cells (Fig 3F).
Efficiency in MALAT1 RNA recovery was checked by RT–qPCR
(Fig 3G). Interaction of MALAT1 with ID4 and p53 was analyzed by
a dot-blot assay, as Western blotting was not applicable due to irre-
versible crosslinking by glutaraldehyde used to fix the cells in this
protocol [49]. As shown in Fig 3H, lower amounts of SRSF1 were
found to be associated with MALAT1 RNA in cells depleted of ID4
or mutant p53 compared with control cells.
Mutant p53 and ID4 control intranuclear localization of MALAT1
It has been previously reported that MALAT1 controls alternative
splicing by interacting with SR proteins and influencing the distribu-
tion of these and other splicing factors in nuclear speckle domains
[10]. Nuclear speckles do not represent major sites of transcription
or splicing, but rather are considered sites from where splicing
factors are recruited to active sites of transcription.
To analyze whether mutant p53 or ID4 expression influences the
subcellular localization of MALAT1, we performed RNA FISH exper-
iments in MDA-MB-468 and SKBR3 cells after mutant p53 or ID4
depletion. In both cell lines, we observed a mixed cell population,
composed of cells showing speckled localization of MALAT1 and
cells showing diffused plus speckled staining (representative images
in Fig EV3C).
◀ Figure 3. ID4 and mutant p53 proteins stabilize binding of splicing factor SRSF1 to MALAT1 lncRNA.A, B p53, ID4, SRSF1 proteins, and MALAT1 RNA levels evaluated by Western blot (A) and RT–qPCR (B) analyses in MDA-MB-468 cells depleted or not of p53R273H or ID4
expression using two different siRNAs for each factor.
C RIP assays performed in MDA-MB-468 cells, depleted or not of ID4 or mutant p53R273H expression, using an antibody directed to SRSF1 (A96, Santa Cruz). MALAT1
RNA abundance was evaluated by RT–qPCR and normalized over GAPDH mRNA.
D RIP assay performed in control and ID4-depleted MDA-MB-468 cells crosslinked with formaldehyde using an antibody directed to SRSF1 (A96, Santa Cruz).
Recruitment of SRSF1 along MALAT1 RNA was evaluated by using 14 couples of primers covering the whole MALAT1 RNA. Numbers indicate the nucleotide
positions on MALAT1 RNA of the couples of primers used.
E PLA assay showing the number of interactions between SRFS1 and p53 protein per nucleus, in control and ID4-depleted cells. The horizontal line represents the
median, the box represents the inter-quartile range and 10–90th percentile interval is shown in whiskers. The black circles represent outliers.
F Western blot showing ID4 and mutant p53 protein levels in MDA-MB-468 cells transfected with the indicated siRNAs and used for ChIRP assays.
G, H ChIRP assay showing the recovery of MALAT1 RNA (G) and its associated SRSF1 protein amount (H) by using a set of biotinylated oligonucleotides complementary
to MALAT1 RNA sequence (Bio-MALAT1), or a set of control oligonucleotides (Bio-CTR), in lysates from control (si-SCR), ID4-depleted (si-ID4), and mutant p53-
depleted (si-p53) MDA-MB-468 cells. Enrichment for MALAT1 RNA was evaluated by RT–qPCR and normalized over GAPDH mRNA (G). Enrichment for SRSF1 protein
was evaluated by dot-blot analysis (H). Quantification was performed by densitometry on a UVITEC instrument, subtracting background signal, and is presented as
folds of Bio-MALAT1 signal over Bio-CTR signal in si-SCR sample.
Data information: Results from at least three biological replicates are shown. Data are presented as mean  SEM. *P ≤ 0.05, **P ≤ 0.005 (two-tailed Student’s t-test).
Source data are available online for this figure.
▸Figure 4. ID4 and mutant p53 proteins control MALAT1 intranuclear distribution.A RNA FISH was performed in control (si-SCR), mutant p53-depleted (si-p53), and ID4-depleted (si-ID4) SKBR3 and MDA-MB-468 cells using StellarisTM fluorescent RNA
probes (Biosearch Technologies, Inc.), spanning the whole MALAT1 lncRNA, and visualized at fluorescence microscope. Nuclei presenting speckled or
diffused+speckled MALAT1 signal were counted, and the results are presented in graph (A). Differences in the intranuclear distribution of MALAT1 were evaluated
by a two-tailed Student’s t-test.
B Images of cells presenting speckled localization of MALAT1 by RNA FISH analysis, as visualized by confocal microcopy. Merges of MALAT1 and DAPI signals are
presented. Scale bars, 10 lm.
C–F ChIRP assay showing the recovery of MALAT1 RNA (C) and its associated histone H3 protein (D,E) by using a set of biotinylated oligonucleotides complementary to
MALAT1 RNA sequence (Bio-MALAT1), or a set of control oligonucleotides (Bio-CTR), in lysates from control (si-SCR), ID4-depleted (si-ID4), and mutant p53-depleted
(si-p53) SKBR3 cells. Enrichment for MALAT1 RNA was evaluated by RT–qPCR and normalized over GAPDH mRNA (C). Enrichment for histone H3 protein was
evaluated by dot-blot analysis (D, E). Quantification was performed by densitometry on a UVITEC instrument, subtracting background signal, and is presented as
folds of Bio-MALAT1 signals over Bio-CTR signals (E). Binding of U2 snRNA to MALAT1 in ChIRP was evaluated by RT–qPCR analysis; U2 snRNA relative enrichment
was obtained by normalization over 18S rRNA (F).
G–J RIP assay was performed in the indicated cell lines, depleted or not of mutant p53 and ID4 expression (panels G, H), after crosslinking with formaldehyde, using
antibodies directed to histone H3 and its modified forms H3K36me3 and H3K27Ac and IgG as negative control (I, J). Binding to MALAT1 RNA was evaluated by RT–
qPCR using six couples of primers spanning MALAT1 sequence. Box plots represent the distribution of the enrichment values of the six considered regions.
Enrichment for each region is calculated as fold over the IgG negative control and is normalized over RPL19 mRNA enrichment. The horizontal line represents the
median, the box represents the inter-quartile range and 10–90th percentile interval is shown in whiskers.
Data information: (C, E, F, G): Results from three biological replicates are shown. Data are presented as mean  SEM. *P ≤ 0.05, **P ≤ 0.005 (paired two-tailed Student’s
t-test).
Source data are available online for this figure.
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As shown in Fig 4A, ID4 or mutant p53 depletion affected
MALAT1 intranuclear localization in both cell lines, leading to a
significant increase in the number of cells showing MALAT1 local-
ized in speckles (Fig 4A).
By confocal microscopy analysis, we also noticed an increase in
the size of MALAT1-positive speckles in cells depleted of ID4 or
mutant p53 (representative images in Fig 4B).
As a higher MALAT1 diffused localization occurs in cells express-
ing ID4 and mutant p53, we investigated whether ID4 and mutant
p53 modulated the localization of MALAT1 on chromatin. To test
this, we analyzed the association between MALAT1 and histone H3
protein. Histone H3 protein is indeed localized exclusively in the
chromatin-associated nuclear fraction in the breast cancer cell lines
used in our study (Fig EV3D and E). Accordingly, MALAT1-asso-
ciated proteins were retrieved using biotinylated oligonucleotides
complementary to MALAT1 lncRNA, and the presence of histone H3
was evaluated by a dot-blot assay. As shown in Fig 4C, similar
amounts of MALAT1 lncRNA were isolated in control and in ID4-
depleted or mutant p53-depleted cells. Of note, we observed that
histone H3 protein was enriched in samples in which biotinylated
oligonucleotides complementary to MALAT1 (Bio-MALAT1) were
used compared to samples using negative control oligonucleotides
(Bio-CTR) (Fig 4D and E). Importantly, the amount of MALAT1-
associated histone H3 clearly decreased after ID4 or mutant p53
interference, suggesting that ID4 and mutant p53 favor the localiza-
tion of MALAT1 to chromatin regions containing H3 (Fig 4D and E).
Accordingly, analysis of MALAT1-associated RNAs by RT–qPCR
showed that U2 snRNA, which was reported to be mostly localized
in nuclear speckles, is enriched in Bio-MALAT1 versus Bio-CTR
samples and that, importantly, its enrichment increases after deple-
tion of ID4 or mutant p53 (Fig 4F).
As reciprocal approach, in RIP assays, we immunoprecipitated
histone H3 protein and evaluated recovery of MALAT1 RNA in
control and mtp53-/ID4-depleted cells (Fig 4G and H). As shown in
Fig 4I and J, we observed a decrease in MALAT1 RNA recovery in
cells depleted of mtp53/ID4 compared to control cells (si-SCR). The
same experiment was performed using antibodies directed to modi-
fied histone H3 forms, such as H3K36me3 (specifically enriched in
exons and able to interact with SRSF1) [50–52] and H3K27Ac (gen-
erally associated with active transcription). H3K36me3 showed a
behavior similar to H3, while H3K27Ac was decreased following
mtp53/ID4 depletion only in MDA-MB-468 cells (Fig 4I and J).
Altogether, these findings indicate that mutant p53 and ID4
proteins may enhance MALAT1 availability at sites of active tran-
scription/splicing.
Mutant p53, ID4, SRSF1, and MALAT1 modulate VEGFA isoform
expression in breast cancer cells
VEGFA is a major player in tumor angiogenesis and exists in multi-
ple splicing isoforms, including the most abundant VEGFA165 and
VEGFA121 (outlined in Fig 5A). Moreover, VEGFA may be expressed
in cells as pro- and anti-angiogenic splicing variants. Anti-angio-
genic isoforms, named VEGFAxxxb, arise from an alternative 3
0
splice site in exon 8 and differ from VEGFAxxx by six amino acids at
the C-terminus (Fig 5A). These alternative six amino acids radically
change the functional properties of VEGFA. SRSF1 protein, interest-
ingly, was reported to favor proximal splice-site (PSS) selection
during splicing of the VEGFA transcript, increasing the production
of pro-angiogenic isoforms [26].
We explored whether the identified ribonucleoprotein (RNP)
complex affects the abundance of VEGFA isoforms. As VEGFA165
and VEGFA121 are the most abundantly expressed isoforms in
cancer cells, we analyzed by RT–qPCR the expression of their pro-
(VEGFA165 and VEGFA121) and anti- (VEGFA165b and VEGFA121b)
angiogenic forms in control MDA-MB-468 cells and in cells depleted
of ID4, mutant p53, MALAT1, or SRSF1. We first evaluated the
mRNA ratio between anti- and pro-angiogenic VEGFA isoforms. As
shown in Fig 5B, the depletion of each component of the RNP
complex led to increased 165b/165 and 121b/121 ratios. Depletion
of hnRNP A1 (a known negative regulator of SRSF1) shows opposite
effect on 165b/165 ratio, compared to si-SRSF1 (Figs 5B and EV4A).
We next analyzed VEGFA protein expression by using antibodies
specifically recognizing VEGFA165b or total VEGFA. According to
RT–qPCR results, we observed that selective depletion of mutant
p53, ID4, SRSF1, or MALAT1 expression in MDA-MB-468 and SKBR3
cells led to increased VEGFA165b protein level (Fig 5C and D).
Increase in VEGFA165b protein level was also confirmed by using
additional siRNAs for mutant p53, ID4, SRSF1, and MALAT1 deple-
tion in MDA-MB-468, SKBR3, and MDA-MB-231 cells (Fig EV4C–G).
We also evaluated the ratio between isoforms VEGFA121 and
VEGFA165. As shown in Fig 5E, a decreased 121/165 ratio was
observed in cells depleted of mutant p53, MALAT1, or SRSF1, and a
decreased 121b/165b ratio was present in all the analyzed siRNA
conditions, suggesting that this complex might favor the shorter
VEGFA121 and VEGFA121b expression. An effect opposite to that of
si-SRSF1 on 121b/165b ratio was observed upon depletion of
hnRNP A1 (Fig 5E). As a control, we analyzed the effect of the
depletion of ID4, mutant p53, MALAT1, or SRSF1 on the production
of two isoforms of the housekeeping gene aldolase A (ALDOA), dif-
fering for the inclusion/exclusion of an exon (Fig EV4B), and we
observed no significant modulation upon interference of all compo-
nents, except SRSF1, whose depletion led to the reduction in the
analyzed isoforms ratio (Fig EV4B).
We next evaluated the expression levels of the various VEGFA
isoforms in the RNA-seq dataset from the breast cancer TCGA study.
This dataset allowed only the analysis of VEGFA121 and VEGFA165
expression, as VEGFAxxxb isoform detection is at low levels in this
dataset. By comparing tumors with missense mutations in the TP53
gene with wt-p53-carrying tumors, we observed that, despite
VEGFA165 being the predominant isoform in both groups, the ratio
of 121/165 was significantly higher in the group with missense
TP53 mutations (Fig 5F). A higher 121/165 ratio was also detected
in ID4-high compared with ID4-low tumors in the group with
missense TP53 mutations.
Mutant p53 and ID4 favor interaction of MALAT1 with VEGFA
precursor mRNA
To evaluate whether the identified RNP complex directly partici-
pates in control of VEGFA isoform expression, we analyzed whether
its mutant p53 component is recruited to VEGFA genomic regions.
Though no longer able to bind the consensus sequences of wt-
p53, the mutant p53 proteins have been shown extensively to
control their targets by tying their genomic regions to interaction
with other DNA-binding proteins [41].
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Chromatin immunoprecipitation (ChIP) analysis detected mutant
p53 protein on the two analyzed genomic regions of the VEGFA gene
in MDA-MB-468 cells (Fig 6A and B), but no significant enrichment
was found on a negative control region (NC). The highest mutant
p53 enrichment was detected on the boundary between intron 7 and
exon 8 (Fig 6A and B) of VEGFA gene. Analysis of mutant p53 bind-
ing to VEGFA pre-mRNA through RIP performed under crosslinking
conditions evidenced a significant enrichment for mutant p53 at the
boundary between intron 7 and exon 8 (Fig 6C), indicating that
mutant p53 is in the right place to influence recruitment of splicing
factors to the transcription complex as it transcribes the DNA.
We next evaluated whether the MALAT1 lncRNA interacts with
VEGFA pre-mRNA. MALAT1 has been shown to interact with target
pre-mRNAs preferentially in intronic regions [53]; interestingly,
bioinformatics analysis predicted the existence of four RNA:RNA
interacting regions between VEGFA intron 7 and MALAT1 (detailed
in Appendix Fig S2A). Recovery of MALAT1-bound RNAs by ChIRP
assay revealed that it interacted with VEGFA pre-mRNA in MDA-
MB-468 (Fig 6D, si-SCR) and SKBR3 (Appendix Fig S2B) cells. Of
note, depletion of ID4 or mutant p53 impaired MALAT1-pre-VEGFA
interaction (Fig 6D and Appendix Fig S2B).
SRSF1 has previously been shown to control VEGFA pre-mRNA
splicing by binding to a short sequence upstream of the proximal
splice site of exon 8 [24]; RIP analysis in control and MALAT1-
depleted MDA-MB-468 cells showed that SRSF1 recruitment on
VEGFA pre-mRNA was decreased by 40% in the absence of
MALAT1 (Fig 6E and Appendix Fig S2C). Binding of SRSF1 to
mature VEGFA mRNA was also impaired by 60% (Fig 6F) after
MALAT1 depletion. Altogether, these results indicate that mutant
p53 and ID4 proteins enable interaction of MALAT1 with VEGFA
pre-mRNA, finally stabilizing binding of SRSF1 to this precursor.
Mutant p53, ID4, SRSF1, and MALAT1 expression in breast cancer
cells favors angiogenesis through repression of VEGFA165b
As the balance between the pro- and anti-angiogenic isoforms of
VEGFA is a major determinant of tumor angiogenesis, we evaluated
whether depletion of the various components of the ribonucleopro-
tein complex that we found to repress VEGFAxxxb impacted the
angiogenic potential of breast cancer cells.
To verify that VEGFAxxxb isoforms have inhibitory activity on
angiogenesis in breast cancer cells, similarly to that reported for
other experimental systems [35,36], we tested the activity of
VEGFA165 and VEGFA165b in a tube formation assay. Serum-free
media with or without recombinant VEGFA were used as controls
(Fig 7A). As shown in Fig 7A and Appendix Fig S3A and B, condi-
tioned medium (CM) from SKBR3 cells transfected with an expres-
sion vector for VEGFA165 caused a significant increase in the
number of meshes formed by HUVEC-derived EA.hy926 endothelial
cells, compared to control CM (CTR). In contrast, CM from SKBR3
cells transfected with the expression vector for VEGFA165b did not
affect basal angiogenic potential, but was able to efficiently abrogate
the angiogenic gain conferred by CM from VEGFA165-expressing
cells (VEGFA165+VEGFA165b). Because we had observed that
◀ Figure 5. ID4, mutant p53, SRSF1 proteins, and lncRNA MALAT1 modulate VEGFA isoform expression.A Schematic representation of the genomic organization of VEGFA gene exons 5-8 and of the mRNAs obtained by their alternative splicing.
B RT–qPCR analysis of transcripts encoding pro-angiogenic (VEGFA165, VEGFA121) and anti-angiogenic (VEGFA165b, VEGFA121b) VEGFA isoforms in MDA-MB-468 cells after
interference of mutant p53, ID4, SRSF1, MALAT1, or hnRNP A1. Ratios of anti- versus pro-angiogenic isoforms are shown.
C Western blot analysis of total VEGFA and anti-angiogenic VEGFA165b proteins. Ratios of VEGFA165b in MDA-MB-468 and SKBR3 cells depleted of p53, ID4, SRSF1, or
MALAT1 over si-SCR sample normalized to total VEGFA are shown.
D A representative Western blot experiment of MDA-MB-468 cells. Numbers indicate ratio between VEGFA165b protein densitometry values in interfered cells (si-p53,
si-ID4, si-SRSF1, si-MALAT1) over si-SCR sample normalized to total VEGFA protein levels.
E Ratio of the expression levels evaluated by RT–qPCR of isoform VEGFA121 over VEGFA165 in MDA-MB-468 cells after interference of mutant p53, ID4, SRSF1, MALAT1, or
hnRNP A1.
F Ratio of the expression levels of isoform VEGFA121 over VEGFA165 obtained by analysis of RNA-seq data from breast cancer samples (TCGA study). The horizontal line
represents the median, the box represents the inter-quartile range and 10–90th percentile interval is shown in whiskers. P-value was calculated by Wilcoxon
signed-rank test.
Data information: Data are presented as mean  SEM. *P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0005, ****P ≤ 0.00005 (Student’s t-test). Results from at least three biological
replicates are shown.
Source data are available online for this figure.
▸Figure 6. lncRNA MALAT1 interacts with VEGFA precursor transcript in ID4- and mutant p53-dependent manner.A, B Recruitment of mutant p53R273H protein on VEGFA genomic regions evaluated by chromatin immunoprecipitation (ChIP) in MDA-MB-468 cells. qPCR was
performed using primers amplifying the regions indicated in panel (A) and a negative control region (NC = intronic region of cyclin B1 gene) previously reported
[62].
C Recruitment of mutant p53R273H protein on VEGFA precursor RNA evaluated by RIP in MDA-MB-468 cells crosslinked with formaldehyde. qPCR was performed
using primers amplifying the regions indicated in panel (A).
D ChIRP assay was performed to recover MALAT1 lncRNA and its associated RNAs by using a set of biotinylated oligonucleotides complementary to MALAT1 RNA
sequence (Bio-MALAT1), or a set of control oligonucleotides (Bio-CTR), in lysates from control (si-SCR), ID4-depleted (si-ID4), and mutant p53-depleted (si-p53) MDA-
MB-468 cells. Enrichment for the indicated transcripts was evaluated by RT–PCR. Mature VEGFA mRNA was analyzed using primers recognizing all isoforms
(reported in Appendix Table S5).
E, F RT–qPCR analysis of VEGFA precursor (E) and mature (F) RNAs performed on RIP experiments from control (si-SCR) and MALAT1-depleted (si-MALAT1) MDA-MB-468
cells immunoprecipitated using an antibody directed to SRSF1. Mature VEGFA mRNA was analyzed using primers recognizing all isoforms (reported in
Appendix Table S5).
Data information: *P < 0.05; ***P < 0.0005 (by Student’s t-test). Results from three biological replicates are shown. Data are presented as mean  SEM.
Source data are available online for this figure.
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VEGFA165b exerts an inhibitory activity on the angiogenic potential
of breast cancer cells, we expected that the depletion of mutant p53
or ID4, as well as the depletion of SRSF1 or MALAT1, leading to
VEGFAxxxb upregulation, would result in a reduced angiogenic
potential of breast cancer cells. To test this hypothesis, we
performed tube formation assays involving the growth of endothe-
lial cells in the presence of CM either from control SKBR3 cells (si-
SCR) or cells depleted of mutant p53, ID4, SRSF1, or MALAT1. As
shown in Fig 7B and Appendix Fig S3B, all four interference condi-
tions significantly reduced the angiogenic potential of SKBR3 cells,
as assessed by counting the number of meshes formed by endothe-
lial cells. To check whether this reduced angiogenic potential was
VEGFA dependent, we tested CM from siRNA-transfected SKBR3
cells, supplemented with recombinant VEGFA protein (rhVEGFA).
A
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rhVEGFA did not affect tube formation in control si-SCR condition
but led to partial recovery of angiogenic potential in the various
interference conditions (Fig 7C). Of note, a complete recovery of
tube formation potential was observed when VEGFA165b blocking
antibody was also added to the CM (Fig 7C and Appendix Fig S3C),
indicating the existence of an inhibitory activity by VEGFA165b in
CM from siRNA-treated cells.
VEGFA signature expression is enriched in basal-like breast
cancers showing mutant p53 and high ID4 levels
We next aimed to explore whether mutant p53 and ID4 expression
is relevant for VEGFA signaling control in human breast cancer. As
VEGFAxxxb isoforms inhibit VEGFA-dependent signal transduction
[33], we expected that VEGFA signaling would be strongly activated
A B
C
Figure 7. ID4, mutant p53, SRSF1, and MALAT1 expression sustains the angiogenic potential of breast cancer cells.
A Angiogenic tube formation assays performed by growing EA.hy926 endothelial cells in the presence of serum-free medium with (100 ng/ml) or without (0 ng/ml)
recombinant VEGFA (rhVEGFA), or conditioned medium (CM) from SKBR3 cells transfected with an empty vector (CTR), an expression vector for VEGFA165 (VEGFA165) or
an expression vector for VEGFA165b (VEGFA165b). The endothelial cells were also tested with a mixture of CM from VEGFA165- and VEGFA165b-overexpressing SKBR3
cells.
B Angiogenic tube formation assays performed by growing EA.hy926 endothelial cells in the presence of CM from SKBR3 cells transfected with control siRNAs (si-SCR) or
si-RNAs directed to ID4 (si-ID4), mutant p53 (si-p53), SRSF1 (si-SRSF1), or MALAT1 (si-MALAT1).
C Angiogenic tube formation assays performed by growing EA.hy926 endothelial cells in the presence of conditioned medium (CM) from SKBR3 cells interfered as in (A)
or plus recombinant VEGFA165 protein (rhVEGFA) alone or in combination with a blocking antibody recognizing VEGFA165b protein (Ab165b).
Data information: Data in (A, B) are presented as mean  SD. **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 (one-way ANOVA). Data in (C) are presented as mean  SD. *P ≤
0.05, **P ≤ 0.01, ***P ≤ 0.001 (two-way ANOVA). Meshes formed by EA.hy926 cells were counted from at least three biological replicates, each including three technical
replicates.
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in cancer cells expressing high levels of ID4 and carrying a mutant
p53 protein.
To test VEGFA signaling activity, we first created a VEGFA
signature by selecting genes that have been reported and vali-
dated in the literature to be directly activated by the VEGFA-
dependent signaling pathway (16-gene VEGFA signature, indicated
as “16-VEGFA”, Appendix Table S3). We then evaluated the
expression of the 16-VEGFA signature using a collection of gene
expression data from basal-like breast cancers (BLBC) of the
METABRIC cohort. BLBC is characterized by the highest incidence
of TP53 gene mutations among all breast cancer subtypes, with
80% of patients carrying TP53 mutations (half of which are
missense mutations) [54]. Of note, High ID4 expression is inver-
sely related to survival specifically in this breast cancer subtype
[47,48].
We then evaluated the expression of the 16-VEGFA signature,
as well as of other VEGFA signatures from the MSigDB database
(http://software.broadinstitute.org/gsea/msigdb/), in relation to
ID4 expression levels, performing gene-set enrichment analysis
(GSEA) on tumors with different TP53 status. As shown in Fig 8A
and B, the 16-VEGFA and two additional signatures were signifi-
cantly enriched in high-ID4- versus low-ID4-expressing tumors
specifically in the mutant p53 group. No significant correlation
was evidenced in the wt-p53 group or in tumors presenting TP53
deletion (ko-p53) (Fig 8A). As SRSF1 is predominantly controlled
by post-translational modifications and MALAT1 by intranuclear
localization, we could not consider their expression levels for
GSEA analysis.
The 16-VEGFA signature was also tested comparing high-ID4-
versus low-ID4-expressing tumors in a second cohort of BLBCs (the
Breast Cancer Compendium Cohort, Appendix Table S4 [55]). 16-
VEGFA signature was significantly enriched in high-ID4 tumors
(FDR = 0.024), with a subset of particularly enriched genes, which
constitute the so-called core (MMP1, COX-2, DSCR1, EGR1, FLT1,
ESM1, CD55).
As both ID4 and VEGFA have been reported to impact survival in
breast cancer, we evaluated whether ID4 and VEGFA signature
cooperate in survival prediction in BLBC. As expected, ID4 as well
as VEGFA signature and VEGFA “core” signature associate with
survival in the Breast Cancer Compendium Cohort (Figs 8D and E,
and EV5A and B). Combination of information about expression
levels of ID4 and VEGFA signature evidenced that tumors with high-
ID4/high-VEGFA signature are associated with a significantly lower
survival compared to low-ID4/low-VEGFA signature (HR = 3.13,
95% CI (1.27–7.68), log-rank test P = 0.0085) (Figs 8D and EV5C).
The remaining combinations (high-ID4/low-VEGFA signature,
low-ID4/high-VEGFA signature) showed an intermediate behavior.
A similar but more significant result was obtained considering the
combination of ID4 and the VEGFA “core” signature (HR = 4.61,
95% CI (1.79–11.88), log-rank test P = 0.0004) (Fig 8F).
Altogether, these data indicate that high expression of ID4 corre-
lates with strongly activated VEGFA signaling specifically in tumors
carrying missense TP53 mutation. Moreover, the combination of
ID4 and VEGFA signature expressions robustly predicts the clinical
outcome of these tumors.
Discussion
In this study, we demonstrated that mutant p53 and ID4 proteins
are able to form a complex with the splicing factor SRSF1 in the
presence of MALAT1 lncRNA in breast cancer cells. The expression
of all these components is required for the formation of this ribo-
nucleoprotein complex. It is possible that additional proteins partici-
pate to the formation of these complexes and this will be clarified
by further studies including in vitro assays to evaluate direct
protein:protein interactions.
The expression of mutant p53 and ID4 was related to the delocal-
ization of MALAT1 from nuclear speckles. This suggests that the
protein complex ID4-mutant p53-SRSF1 may cover the MALAT1
speckle localization sequence and thereby relocate it out of speckles.
Alternatively, it is also possible that mutant p53 and ID4 control the
expression of proteins required for the localization of MALAT1 to
speckles, for example, RNPS1, SRm160, and IBP160 [11], although
the direct interaction between the three proteins and MALAT1
argues against this being required.
Our results also indicate that mutant p53 and ID4 expression
directs MALAT1 to chromatin regions that contain histone H3. It is
possible that this makes MALAT1 more available at sites of active
transcription/splicing on the chromatin. We indeed found a higher
level of interaction of MALAT1 with histone H3 (exclusively local-
ized in chromatin) and a lower level of interaction of MALAT1 with
U2 snRNA (typically localized in nuclear speckles) in cells express-
ing mutant p53 and ID4, compared to cells depleted of mutant p53
or ID4.
SRSF1 activity is modulated by phosphorylation events [23,56].
Specifically, hypophosphorylated SRSF1 is enriched in the cytoplasmic
compartment where it favors translation of its target mRNAs. The
SRPK splicing factor kinases are responsible for SRSF1 phosphoryla-
tion in the cytoplasm, leading to its nuclear translocation and accumu-
lation in nuclear speckles. There, a family of Cdc2-like nuclear kinases
(Clk kinases), as well as SRPKs, act on already-phosphorylated SRSF1,
▸Figure 8. VEGFA signature expression associates with ID4 expression in mutant p53-carrying basal-like breast cancers.A Gene-set enrichment analysis (GSEA) of VEGFA-dependent signatures in ID4-high versus ID4-low basal-like breast cancers of the METABRIC cohort with different
TP53 status. NES, normalized enrichment score; FDR, false discovery rate.
B Enrichment plot obtained through GSEA of the 16-VEGFA signature in ID4-high versus ID4-low basal-like breast cancer samples with mutated TP53 gene.
C Enrichment plot obtained through GSEA of 16-VEGFA signature in high-ID4 versus low-ID4 basal-like breast cancer samples from the Breast Cancer Compendium
Cohort. The black vertical bars indicate the positions of single components of the VEGFA-activity signature in the samples. The green line shows the cumulative
score of the enrichment of the examined 16-VEGFA signature. A positive enrichment score indicates positive correlation between the 16-VEGFA signature and ID4
mRNA expression.
D–F Survival and Kaplan–Meier analyses performed on 201 basal-like breast cancer patients from the Breast Cancer Compendium Cohort showing the predictive value
on overall survival of the expression level of ID4 mRNA, VEGFA signatures, and their combinations. Tumors were divided into high- or low-ID4 expression categories
based on the median of ID4 expression in the series.
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leading to its hyperphosphorylation, which causes its release from
speckles to areas where the splicing reaction takes place [23]. Further
investigation will enable the deciphering of whether the binding of
mutant p53 and ID4 to SRSF1 is responsible for the modulation of
phosphorylation events, thus influencing the interaction between
SRSF1 and MALAT1.
SRSF1 has been reported to promote PSS selection in terminal
exon choice during splicing of the VEGFA mRNA, thus favoring the
production of pro-angiogenic isoforms at the expense of anti-angio-
genic isoforms. Accordingly, we observed that ID4 and mutant p53
proteins, which promote stabilization of the binding of SRSF1 to
MALAT1, inhibit the production of anti-angiogenic VEGFAxxxb
isoforms and increase the VEGFA 121/165 isoform ratio. Repression
of VEGFAxxxb has been previously shown in various malignancies
including melanoma, and renal and colorectal carcinoma. However,
the molecular mechanism governing the switch from the anti-angio-
genic VEGFA isoforms, which are predominant in non-transformed
cells, to the pro-angiogenic ones, which are the most expressed in
cancer cells, has yet to be exhaustively deciphered. We show here
that in breast cancer cells, a mechanism promoting the repression
of VEGFAxxxb forms relies on the formation of the quaternary
complex containing SRSF1 and MALAT1, previously characterized
to interact, and the ID4 and mutant p53 proteins, these being
ultimately required for the formation of a stable RNP complex. The
depletion of individual components of the RNP complex is suffi-
cient to release the expression of VEGFAxxxb isoforms and to
reduce the angiogenic potential of breast cancer cells. Interestingly,
MALAT1 has been recently shown to promote angiogenesis driven
by neuroblastoma cells through its ability to modulate FGF2
expression [57].
VEGFAxxxb isoform expression has been related to the inhibition
of VEGFR2 signaling. Accordingly, we observed enrichment for
VEGFA signature expression in breast tumors characterized by the
presence of a missense mutation in TP53 gene and High ID4 expres-
sion. Further investigation, focused on the examination of phospho-
rylation status of SRSF1 and intranuclear localization of MALAT1,
in breast cancer sections, will allow the analysis of their association
with TP53 status, ID4, VEGFA signature expression, and survival.
In aggregate, our findings discover a novel mechanistic layer
through which gain–of-function mutant p53 proteins enhance angio-
genesis. Thus, the disassembling of the ribonucleoprotein complex
comprising mutant p53/ID4/SRSF1/MALAT1 might hold therapeutic
premise for mutant p53 breast cancers.
Materials and Methods
Cell lines, siRNA and plasmid transfections, and
retroviral infections
All cell lines were grown at 37°C, 5% CO2, in medium containing
10% fetal bovine serum (FBS) and penicillin/streptomycin. SKBR3
(ATCC) cells were grown in McCoy’s 5A medium, MDA-MB-468
(ATCC) in DMEM F12 medium, MDA-MB-231 (ATCC), MCF7
(ATCC), and H1299 (ATCC) in RPMI medium, HEK T293 cells in
DMEM AQ medium. OVCAR-3 (ATCC) cells were grown in RPMI
medium with 20% fetal bovine serum (FBS) plus 0.01 mg/ml
bovine insulin and penicillin/streptomycin. Stable cell lines SKBR3
and MDA-MB-468 (sh-p53 and wt-p53) were obtained by lentiviral
transduction. The system is composed of a vector containing both
shRNA targeting endogenous mutant p53 and a sequence encoding
wild-type p53. The sequence coding for wt-p53 possesses silent
mutations in a region recognized by shRNA. shRNA-binding site:
GAC TCC AGT GGT AAT CTA C (shRNA sequence); modified p53
sequence: GAC TCG AGC GGC AAC CTC C. Substituted nucleotides
are underlined.
For si-RNA transfection, the GenMute siRNA&DNA (SignaGen)
transfection reagent or RNAiMax (Thermo Fisher) was used follow-
ing the manufacturer’s instructions. List of siRNAs used in the study
is enclosed in Appendix Table S5.
Western blot
For the Western blot analysis, cells were lysed in RIPA buffer. The
protein concentration was measured using a BCA protein assay kit
(Thermo Scientific). The lysate was mixed with 4× Laemmli buffer.
Total protein extracts were resolved on polyacrylamide gel and then
transferred onto nitrocellulose membrane. The following primary
antibodies were used: DO-1 and CM-1 (anti-p53, kind gift from B.
Vojtesek), A96 (anti-SRSF1, Santa Cruz), H70 and B-5 (anti-ID4,
Santa Cruz), M106 (anti-ID4, CalBioreagents), ab46154 (anti-
VEGFA, Abcam), ab14994 (anti-VEGFA165b, Abcam), ab16047 (anti-
laminB1, Abcam), E2F1 (Santa Cruz), and H3 and modified H3
forms (Abcam). For detection, two types of secondary antibodies
were used: antibodies fused with HRP for chemiluminescence detec-
tion, and goat anti-mouse-800 and goat anti-rabbit-680 LicorOdyssey
antibodies for detection with an infrared scanner.
RNA fluorescence in situ hybridization (FISH)
To study the subcellular localization of MALAT1, fluorescence in
situ hybridization was performed using a mixture of 48 fluorescent
(Quasar 570) StellarisTM RNA probes (Biosearch Technologies, Inc.)
distributed evenly along the MALAT1 RNA. Cells were fixed with
3.7% formaldehyde in PBS and permeabilized with 70% ethanol for
at least 24 h. Then, the manufacturer’s protocol was followed.
Staining was visualized with a fluorescence microscope, and
patterns of MALAT1 distribution (speckled or diffused plus speck-
led) were counted manually using ImageJ software. Microscope
image evaluation was performed independently and in blinded
manner by two investigators.
Combined immunofluorescence–RNA FISH
Cells were fixed using 3% paraformaldehyde (PFA) for 10 min at
RT, permeabilized with 0.25% v/v Triton X-100 in PBS for 8 min,
blocked 20 min in PBS/1% w/v BSA, and incubated with primary
anti-p53 1:250 (FL393, Santa Cruz). Secondary antibody (Alexa
Fluor 488, 1:500) was incubated for 40 min. Cells were post-fixed
using 3% PFA for 10 min at RT and subjected to RNA FISH as
described above. Fluorescence high-resolution images of fixed cells,
labeled with DAPI (cell nuclei), Alexa Fluor 488 (p53 protein), and
Quasar 570 (MALAT1 RNA), were acquired through an inverted
Olympus IX83 microscope (Olympus Europe, Hamburg, Germany),
equipped with an UPLSAPO 60× water immersion objective (NA
1.2) with a confocal aperture of 600 microns, for a theoretical
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optical resolution of 210 nm (horizontal) and 3.8 microns (vertical).
The PMT voltages were adjusted such that no pixels were saturated
in the image. Colocalization analysis between green and red chan-
nels was completed following a well-established protocol. Per each
field of view, the DAPI channel was used to identify ROIs selecting
the nuclei portion of the image. Each ROI, then, was analyzed to
determine relevant statistical parameters (Pearson’s correlation
coefficient R [58], Manders colocalization coefficients M1 and M2
[59], and Li intensity correlation quotient ICQ [60]) by an automatic
threshold procedure [61]. The average results from all the ROIs for
each sample are reported in Fig 1E.
Proximity ligation assay and immunofluorescence
To study protein–protein interactions in a quantitative manner, the
Duolink proximity ligation assay (PLA) was used (Sigma-Aldrich).
Cells cultured on a cover glass were fixed in 3.7% formaldehyde in
PBS, permeabilized for 10 min with 0.25% Triton X-100 in PBS, and
blocked for 30 min with Duolink blocking buffer. Further, the
manufacturer protocol was followed. The nuclei were stained with
DAPI. ImageJ software was used to count the positive signals. The
samples for immunofluorescence were prepared in the same way as
for PLA. Microscope image evaluation was performed independently
and in blinded manner by two investigators.
RNA isolation and RT–qPCR
The RNA was isolated with TRIzol (Sigma), and its concentration
was measured using a NanoDrop 2000 (NanoDrop Technologies,
Wilmington, DE, USA). Reverse transcription was performed with
SuperScript II or MMLV-RT (Invitrogen). qPCR was carried out on
ABI PRISM 7500 Fast Sequence Detection System (Applied Biosys-
tems, Carlsbad, CA, USA). Primers used for PCR analyses are listed
in Appendix Table S5. The expression values of mRNAs were calcu-
lated by standard curve method and normalized over the indicated
housekeeping control genes. P-values were calculated with two-
tailed Student’s t-test. Statistically significant results were referred
with a P-value < 0.05.
Co-immunoprecipitation
The cells were lysed in buffer composed of 50 mM HEPES pH 7.4,
160 mM NaCl, 10 mMMgCl2, 5 mM KCl, 2 mM EDTA pH 8.0, 1 mM
DTT, 0,5% Triton X-100, and protease and phosphatase inhibitors.
1 mg of total protein lysate was used for immunoprecipitation with
Dynabeads (Invitrogen). After immunoprecipitation, the beads
were boiled with Laemmli buffer supplemented with 1 mM DTT.
The immunoprecipitated proteins were analyzed by Western blot.
RNA immunoprecipitation (RIP) on native lysates and RIP-chip
The Dynabeads (Invitrogen) were preincubated with antibodies
specific to the target protein for 24 h at 4°C in NT2 buffer (50 mM
Tris–HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.05% NP-40). The
following antibodies were used: DO1 (Santa Cruz) and Ab7 (Cal-
biochem) for p53 IP; H70 (Santa Cruz) and ab49261 (Abcam) for
ID4 IP; sc-33652 SF2/ASF (96) (Santa Cruz) for SRSF1 IP. To obtain
native lysates, cells were trypsinized, pelleted, and lysed in PLB
buffer (10 mM HEPES pH 7.0, 100 mM KCl, 5 mM MgCl2, 0.5%
NP-40, 25 mM EDTA pH 8.0, 1 mM DTT, 100 U/ml RNaseOUT, and
protease and phosphatase inhibitors). For every sample, antibody-
coated beads were suspended in 850 ll of NET buffer (850 ll NT2
supplemented with 10 ll of 100 mM DTT, 30 ll of 0.5 M EDTA,
and 5 ll of RNaseOUT). 1 mg of total protein lysate in 100 ll PLB
was added to the beads and incubated for 1 h at room temperature.
After immunoprecipitation, beads were washed four times with
1 ml of ice-cold NT2 buffer and then resuspended in 100 ll of NET
buffer plus 100 ll of proteinase K buffer (200 mM Tris–HCl pH 7.5,
20 mM EDTA pH 8.0, and 100 mM NaCl, 2% SDS). Samples were
incubated with 30 lg of proteinase K for 30 min at 55°C. RNA was
isolated from the supernatant with TRIzol (Sigma) according to the
manufacturer’s protocol. The obtained cDNA was further analyzed
by real-time PCR. Enrichments were normalized over GAPDH and/
or RPL19 expression.
RNA obtained from RIP experiments was subjected to gene
expression profiling using the Affymetrix platform (Human Gene 1.0
ST arrays) according to the manufacturer’s instructions. Scanned
image files (.CEL) were processed, normalized (RMA-Sketch Quan-
tile), and log2-transformed using Affymetrix Expression Console.
Transcripts with an expression value lower than 6 were filtered out
and not considered for further analyses. Transcripts significantly
enriched in samples immunoprecipitated in the presence of anti-ID4
antibodies (H-70 from Santa Cruz and ab49261 from Abcam) as
compared to IgG negative controls were selected using the super-
vised comparison analysis of the Analyzer software [62]. Specifi-
cally, transcripts enriched more than 2.5-fold with both antibodies,
when compared to IgG negative control, were used for subsequent
analysis.
RNA immunoprecipitation (RIP) on lysates from crosslinked cells
Cells were crosslinked with 254-nm UV light 800 mJ/cm2 (using
10-cm dish with 2.5 ml PBS) or with formaldehyde (F.A.) solution
(50 mM HEPES-KOH pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 11% formaldehyde, ddH2O) 1% final concentration, 10 min,
RT. Nuclei were isolated and resuspended in lysis buffer (Tris–HCl
pH 7.5 50 mM, EDTA 1 mM, SDS 0.5%, DTT 1 mM), using 200 ll
for each planned IP sample, and sonicated to obtain a smear not
higher than 500 bp. Lysate was treated with DNase (DNAfree,
Ambion) and diluted with 400 ll of correction buffer (NP-40, 0.625%,
DOC, 0.312%, MgCl2, 5.6 mM, Tris–HCl pH 7.5, 47.5 mM, NaCl,
187.5 mM, glycerol, 12.5%, DTT 1 mM). IP was carried out overnight
at +4°C. For histone H3 IP, the following ChIP-grade antibodies from
Abcam were employed: ab1791 (H3); ab4729 (H3K27Ac); ab9050
(H3K36me3). IP washing and proteinase K digestion were carried out
as above, crosslinking was reversed by incubation at 70°C for 30 min,
and RNA was recovered by TRIzol extraction.
ChIRP
ChIRP was performed as described [49]. 20 million cells were used
for each condition. The oligonucleotides used for MALAT1 immuno-
precipitation are listed in Appendix Table S5. Biotinylated oligo-
nucleotides were recovered using Dynabeads MyOneTM Streptavidin
C1 (Invitrogen). After the washing steps, 60% of the recovered mate-
rial was used for protein purification, 20% for RNA purification, and
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20% for DNA purification. Proteins abundance was evaluated by dot-
blot analysis. Specifically, half of volume of the recovered proteins
was loaded in the wells of a Bio-Dot apparatus (Bio-Rad), then trans-
ferred to the nitrocellulose membrane, and used for blotting using
antibodies directed against SRSF1 (A96, Santa Cruz) or histone H3
(Abcam).
Chromatin immunoprecipitation (ChIP)
Formaldehyde crosslinking and chromatin immunoprecipitation
were performed as previously described [38]. The chromatin
solution was immunoprecipitated with sheep anti-p53 serum (Ab7,
Calbiochem), anti-p53 (Santa Cruz, sc-6243), or IgG as negative
control. Cyclin B1 first intron was amplified as negative control
region as described [63]. P-values were calculated with two-tailed
t-test. Statistically significant results were referred with
P-value < 0.05.
Tube formation assay
To perform the tube formation assay, we used the EA.hy926 cell
line, a hybridoma of HUVEC, and A549 cell lines. EA hy926 cells
were infected with a lentiviral vector constitutively expressing
tdTomato fluorescent protein. Before the experiment, 80% confluent
cells were starved for 24 h in serum-free medium (SFM). Experi-
ments were performed on 96-well l-slides for angiogenesis (Ibidi)
coated with 10 ll/well Growth Factor Reduced Matrigel (BD). After
Matrigel gelation, 35 ll of conditioned medium (CM) was added.
CM was obtained by cultivation of cancer cells for 48 h in a medium
with 1% FBS. As a positive control, 100 ng/ml of recombinant
human VEGFA165 (PeproTech) was used. Fresh medium with 1%
FBS served as a negative control. Then, 35 ll of cells suspended in
SFM was added to a final density of 11,000 cells/well. Cell suspen-
sion was supplemented with recombinant human VEGFA165 (Pepro-
Tech, rhVEGFA, 20 ng/ml) or anti-VEGFA165b antibody (ab14994,
Abcam, 25 nM) and rhVEGFA together. Pictures were taken after
8 h on a wide-field fluorescence microscope. Image analysis was
performed using the ImageJ plugin for angiogenic assays.
Collection and processing of breast cancer gene expression data
The breast cancer compendium was generated as described [55].
Briefly, we started from a collection of 4,640 samples from 27 major
datasets comprising microarray data of breast cancer samples
annotated with histological tumor grade and clinical outcome. The
PAM50 classifier for the identification of breast cancer molecular
subtypes [64] encoded in the genefu R package [65] classified 751
breast cancer samples as basal, of which 201 presented follow-up
information.
The METABRIC dataset was downloaded from the European
Genome-Phenome Archive (EGA, http://www.ebi.ac.uk/ega/)
under accession number EGAD00010000210 [66]. The dataset
comprises microarray data and clinical annotations for 997 breast
cancer samples, of which 118 were annotated as basal using
PAM50. The status of TP53 was derived from Dataset EV1 of Silwal-
Pandit and colleagues [67] and merging molecular subtyping and
TP53 status returned 35 “missense” mutant p53, 22 wt-p53, and 30
ko-p53 basal breast cancer samples.
VEGFA isoform level in breast cancer patients was analyzed
using the RNA-seq data of the TCGA Breast Invasive Carcinoma
Dataset [54,68] comprising 672 “missense” mutant p53 and 173 wt-
p53 samples. RNA-seq data were downloaded from the Firehose
Broad GDAC website (http://gdac.broadinstitute.org/) selecting
signals normalized at isoform level.
Survival analysis
Basal tumors in breast cancer compendium were classified as “Low
ID4 expression” or “High ID4 expression” by considering the expres-
sion of the 209291_at Affymetrix probeset representing ID4 and
using the median expression value in the cohort as the threshold.
To identify two groups of tumors with either high or low-VEGFA
signature, we used a classification rule based on the VEGFA signa-
ture score, calculated by summarizing the standardized expression
levels of the genes in the signature into a combined score with zero
mean. Tumors were classified as “VEGFA signature Low” if the
combined score was negative and as “VEGFA signature High” if the
combined score was positive. The same rule was applied with the
VEGFA core signature. To evaluate the prognostic value of the
signatures, we estimated the patients’ survival probability using the
Kaplan–Meier method. The Kaplan–Meier curves were compared
using the log-rank (Mantel–Cox) test, and P-values were calculated
according to the standard normal asymptotic distribution. Cox
proportional hazards models were constructed to estimate the
hazard ratios.
Over-representation analysis
Gene-set enrichment analysis (GSEA) was used to investigate
whether High ID4 expression was associated with elevated activity
of VEGFA signaling pathway. GSEA software (http://www.broadin
stitute.org/gsea/index.jsp) was applied on log2 expression data of
basal tumors classified as “High ID4 expression” or as “Low ID4
expression”. GSEA returned the VEGFA signature as upregulated in
phenotype “High ID4 expression” (enrichment score ES > 0) and
significantly enriched at FDR < 5% when using 1,000 permutations
of gene sets.
Expanded View for this article is available online.
Acknowledgements
We thank M. Olszewski and M. Wawrzyniak for the preliminary experiments
with the tube formation assay. We are indebted to P. Czerwinska and M.
Klimczak who provided the modified SKBR3 and MDA-MB-468 cell lines and
to K. Zabłocki for EA.hy926 cell line. We thank Prof. Eytan Domany, Dr. A.
Zeisel, and Dr. A. Yitzhaky for the use of the “Analyzer” software. This work
was supported by Italian Ministry of Health grant (GR-2011-02348567) and
AIRC (MFAG10728) to GF; MIUR Epigen (13/05/R/42) and AIRC (IG14455) to
GB; a MAESTRO NZ1/00089 grant from the National Science Centre of
Poland to MP, AZ, and MZ; The Foundation for Polish Science within the
International PhD Project “Studies of nucleic acids and proteins—from basic
to applied research” (co-financed from the European Union—Regional Devel-
opment Fund) and FishMed Project (supported by the European Commission
under FP7 GA No 316125) to MP; AIRC Special Program Molecular Clinical
Oncology “5 per mille” and MIUR EPIGEN—Italian Flagship Project Epige-
nomics to S.B.
EMBO reports ª 2017 The Authors
EMBO reports lncRNA MALAT1 inhibits anti-angiogenic VEGFAxxxb expression Magdalena Pruszko et al
18
Published online: June 26, 2017 
Author contributions
GF, GB, AZ, MZ, and DOB designed research. MP, GF, SD, FG, EM, SDA, SDP, FF
performed the experiments. SB and MF performed bioinformatics analyses. GF
and MP wrote the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
References
1. Zong X, Tripathi V, Prasanth KV (2011) RNA splicing control: yet another
gene regulatory role for long nuclear noncoding RNAs. RNA Biol 8:
968 – 977
2. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N,
Brandt B, Buerger H, Bulk E et al (2003) MALAT-1, a novel noncoding
RNA, and thymosin beta4 predict metastasis and survival in early-stage
non-small cell lung cancer. Oncogene 22: 8031 – 8041
3. Jadaliha M, Zong X, Malakar P, Ray T, Singh DK, Freier SM, Jensen T,
Prasanth SG, Karni R, Ray PS et al (2016) Functional and prognostic signif-
icance of long non-coding RNA MALAT1 as a metastasis driver in ER nega-
tive lymph node negative breast cancer. Oncotarget 7: 40418 – 40436
4. Gutschner T, Hammerle M, Diederichs S (2013) MALAT1 – a paradigm
for long noncoding RNA function in cancer. J Mol Med 91: 791 – 801
5. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim
Y, MacLeod AR, Krainer AR, Norton L et al (2016) Differentiation of
mammary tumors and reduction in metastasis upon Malat1 lncRNA
loss. Genes Dev 30: 34 – 51
6. Wilusz JE, Freier SM, Spector DL (2008) 30 end processing of a long
nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA.
Cell 135: 919 – 932
7. Wilusz JE, JnBaptiste CK, Lu LY, Kuhn CD, Joshua-Tor L, Sharp PA (2012)
A triple helix stabilizes the 30 ends of long noncoding RNAs that lack
poly(A) tails. Genes Dev 26: 2392 – 2407
8. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess
A (2007) A screen for nuclear transcripts identifies two linked noncoding
RNAs associated with SC35 splicing domains. BMC Genom 8: 39
9. Spector DL, Lamond AI (2011) Nuclear speckles. Cold Spring Harb
Perspect Biol 3: a000646
10. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett
CF, Sharma A, Bubulya PA et al (2010) The nuclear-retained noncoding
RNA MALAT1 regulates alternative splicing by modulating SR splicing
factor phosphorylation. Mol Cell 39: 925 – 938
11. Miyagawa R, Tano K, Mizuno R, Nakamura Y, Ijiri K, Rakwal R, Shibato J,
Masuo Y, Mayeda A, Hirose T et al (2012) Identification of cis- and
trans-acting factors involved in the localization of MALAT-1 noncoding
RNA to nuclear speckles. RNA 18: 738 – 751
12. Anko ML, Muller-McNicoll M, Brandl H, Curk T, Gorup C, Henry I, Ule J,
Neugebauer KM (2012) The RNA-binding landscapes of two SR proteins
reveal unique functions and binding to diverse RNA classes. Genome Biol
13: R17
13. Sanford JR, Wang X, Mort M, Vanduyn N, Cooper DN, Mooney SD, Eden-
berg HJ, Liu Y (2009) Splicing factor SFRS1 recognizes a functionally
diverse landscape of RNA transcripts. Genome Res 19: 381 – 394
14. Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, Dorrestein PC,
Rosenfeld MG (2011) ncRNA- and Pc2 methylation-dependent gene relo-
cation between nuclear structures mediates gene activation programs.
Cell 147: 773 – 788
15. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y,
Gorospe M, Prasanth SG, Lal A et al (2013) Long noncoding RNA MALAT1
controls cell cycle progression by regulating the expression of oncogenic
transcription factor B-MYB. PLoS Genet 9: e1003368
16. Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, Xuan Z,
Zhang MQ, Sedel F, Jourdren L, Coulpier F et al (2010) A long nuclear-
retained non-coding RNA regulates synaptogenesis by modulating gene
expression. EMBO J 29: 3082 – 3093
17. Zhang B, Arun G, Mao YS, Lazar Z, Hung G, Bhattacharjee G, Xiao X,
Booth CJ, Wu J, Zhang C et al (2012) The lncRNA Malat1 is dispensable
for mouse development but its transcription plays a cis-regulatory role
in the adult. Cell Rep 2: 111 – 123
18. Nakagawa S, Ip JY, Shioi G, Tripathi V, Zong X, Hirose T, Prasanth KV
(2012) Malat1 is not an essential component of nuclear speckles in
mice. RNA 18: 1487 – 1499
19. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR (2007) The
gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat
Struct Mol Biol 14: 185 – 193
20. Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R,
Muthuswamy SK, Krainer AR (2012) The splicing factor SRSF1 regulates
apoptosis and proliferation to promote mammary epithelial cell trans-
formation. Nat Struct Mol Biol 19: 220 – 228
21. Li X, Wang J, Manley JL (2005) Loss of splicing factor ASF/SF2 induces G2
cell cycle arrest and apoptosis, but inhibits internucleosomal DNA frag-
mentation. Genes Dev 19: 2705 – 2714
22. Das S, Krainer AR (2014) Emerging functions of SRSF1, splicing factor and
oncoprotein, in RNA metabolism and cancer.Mol Cancer Res 12: 1195 –1204
23. Risso G, Pelisch F, Quaglino A, Pozzi B, Srebrow A (2012) Regulating the regu-
lators: serine/arginine-rich proteins under scrutiny. IUBMB Life 64: 809 – 816
24. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M,
Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR et al
(2010) Regulation of vascular endothelial growth factor (VEGF) splicing
from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic
strategy for angiogenesis. J Biol Chem 285: 5532 – 5540
25. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat
D, Gillatt D, Harper SJ (2002) VEGF165b, an inhibitory splice variant of
vascular endothelial growth factor, is down-regulated in renal cell carci-
noma. Can Res 62: 4123 – 4131
26. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill
AJ, Ladomery MR, Harper SJ, Bates DO (2008) Expression of pro- and
anti-angiogenic isoforms of VEGF is differentially regulated by splicing
and growth factors. J Cell Sci 121: 3487 – 3495
27. Harper SJ, Bates DO (2008) VEGF-A splicing: the key to anti-angiogenic
therapeutics? Nat Rev Cancer 8: 880 – 887
28. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ
(2005) Diabetic retinopathy is associated with a switch in splicing from
anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
Diabetologia 48: 2422 – 2427
29. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO,
Cui TG, Sugiono M, Waine E, Perrin R et al (2004) VEGF165b, an inhibi-
tory vascular endothelial growth factor splice variant: mechanism of
action, in vivo effect on angiogenesis and endogenous protein expres-
sion. Can Res 64: 7822 – 7835
30. Peiris-Pages M, Harper SJ, Bates DO, Ramani P (2010) Balance of pro-
versus anti-angiogenic splice isoforms of vascular endothelial growth
factor as a regulator of neuroblastoma growth. J Pathol 222: 138 – 147
31. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh
GI, Cheung MK, Ni L, Kase S, Rennel ES et al (2011) WT1 mutants reveal
ª 2017 The Authors EMBO reports
Magdalena Pruszko et al lncRNA MALAT1 inhibits anti-angiogenic VEGFAxxxb expression EMBO reports
19
Published online: June 26, 2017 
SRPK1 to be a downstream angiogenesis target by altering VEGF splic-
ing. Cancer Cell 20: 768 – 780
32. Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y,
Miner JH, Leuschner I, Engers R, Everding AS et al (2007) Impaired
glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
J Am Soc Nephrol 18: 719 – 729
33. Peiris-Pages M (2012) The role of VEGF 165b in pathophysiology. Cell
Adh Migr 6: 561 – 568
34. Cebe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A,
Manlius C, Wood J, Ballmer-Hofer K (2006) A VEGF-A splice variant
defective for heparan sulfate and neuropilin-1 binding shows attenu-
ated signaling through VEGFR-2. Cell Mol Life Sci 63: 2067 – 2077
35. Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard J, Sugiono
M, Gillatt D, Kleinerman E, Bates D et al (2008) The endogenous anti-
angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in
mice. Br J Cancer 98: 1250 – 1257
36. Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR,
Paraskeva C, Zaccheo O, Hassan AB et al (2008) VEGF 165 b, an antian-
giogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in
experimental colorectal carcinoma: balance of pro- and antiangiogenic
VEGF-A isoforms has implications for therapy. Br J Cancer 98:
1366 – 1379
37. Kazemi M, Carrer A, Moimas S, Zandona L, Bussani R, Casagranda B,
Palmisano S, Prelazzi P, Giacca M, Zentilin L et al (2016) VEGF121 and
VEGF165 differentially promote vessel maturation and tumor growth in
mice and humans. Cancer Gene Ther 23: 125 – 132
38. Fontemaggi G, Dell’Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F,
Terrenato I, Mottolese M, Muti P, Domany E et al (2009) The execution
of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor
neo-angiogenesis. Nat Struct Mol Biol 16: 1086 – 1093
39. Oren M, Rotter V (2010) Mutant p53 gain-of-function in cancer. Cold
Spring Harb Perspect Biol 2: a001107
40. Goh AM, Coffill CR, Lane DP (2011) The role of mutant p53 in human
cancer. J Pathol 223: 116 – 126
41. Muller PA, Vousden KH (2014) Mutant p53 in cancer: new functions and
therapeutic opportunities. Cancer Cell 25: 304 – 317
42. Walerych D, Napoli M, Collavin L, Del Sal G (2012) The rebel angel:
mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33:
2007 – 2017
43. Dell’Orso S, Ganci F, Strano S, Blandino G, Fontemaggi G (2010) ID4: a
new player in the cancer arena. Oncotarget 1: 48 – 58
44. Wen YH, Ho A, Patil S, Akram M, Catalano J, Eaton A, Norton L, Benezra
R, Brogi E (2012) Id4 protein is highly expressed in triple-negative
breast carcinomas: possible implications for BRCA1 downregulation.
Breast Cancer Res Treat 135: 93 – 102
45. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox
SB, Ichihara S, Jacquemier J, Lakhani SR et al (2011) Basal-like and
triple-negative breast cancers: a critical review with an emphasis on
the implications for pathologists and oncologists. Mod Pathol 24:
157 – 167
46. Baker LA, Holliday H, Swarbrick A (2016) ID4 controls luminal lineage
commitment in normal mammary epithelium and inhibits BRCA1
function in basal-like breast cancer. Endocr Relat Cancer 23:
R381 – R392
47. Thike AA, Tan PH, Ikeda M, Iqbal J (2016) Increased ID4 expression,
accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins
in triple-negative breast cancer, adversely affects survival. Histopathol-
ogy 68: 702 – 712
48. Junankar S, Baker LA, Roden DL, Nair R, Elsworth B, Gallego-Ortega D,
Lacaze P, Cazet A, Nikolic I, Teo WS et al (2015) ID4 controls mammary
stem cells and marks breast cancers with a stem cell-like phenotype.
Nat Commun 6: 6548
49. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY (2011) Genomic maps of
long noncoding RNA occupancy reveal principles of RNA-chromatin
interactions. Mol Cell 44: 667 – 678
50. Spies N, Nielsen CB, Padgett RA, Burge CB (2009) Biased chromatin signa-
tures around polyadenylation sites and exons. Mol Cell 36: 245 – 254
51. Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, Ahringer J (2009)
Differential chromatin marking of introns and expressed exons by
H3K36me3. Nat Genet 41: 376 – 381
52. Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA (2012)
Psip1/Ledgf p52 binds methylated histone H3K36 and splicing factors and
contributes to the regulation of alternative splicing. PLoS Genet 8: e1002717
53. Engreitz JM, Sirokman K, McDonel P, Shishkin AA, Surka C, Russell P,
Grossman SR, Chow AY, Guttman M, Lander ES (2014) RNA-RNA interac-
tions enable specific targeting of noncoding RNAs to nascent Pre-mRNAs
and chromatin sites. Cell 159: 188 – 199
54. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of
human breast tumours. Nature 490: 61 – 70
55. Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M,
Grifoni D, Pession A, Zanconato F, Guzzo G et al (2015) Aerobic glycolysis
tunes YAP/TAZ transcriptional activity. EMBO J 34: 1349 – 1370
56. Misteli T, Caceres JF, Clement JQ, Krainer AR, Wilkinson MF, Spector DL
(1998) Serine phosphorylation of SR proteins is required for their recruit-
ment to sites of transcription in vivo. J Cell Biol 143: 297 – 307
57. Tee AE, Liu B, Song R, Li J, Pasquier E, Cheung BB, Jiang C, Marshall GM,
Haber M, Norris MD et al (2016) The long noncoding RNA MALAT1
promotes tumor-driven angiogenesis by up-regulating pro-angiogenic
gene expression. Oncotarget 7: 8663 – 8675
58. Manders EM, Stap J, Brakenhoff GJ, van Driel R, Aten JA (1992) Dynamics
of three-dimensional replication patterns during the S-phase, analysed
by double labelling of DNA and confocal microscopy. J Cell Sci 103(Pt 3):
857 – 862
59. Manders EMM, Verbeek FJ, Aten JA (1993) Measurement of colocalization
of objects in dual-color confocal images. J Microsc 169: 375 – 382
60. Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, Stanley EF (2004) A syntaxin 1,
Galpha(o), and N-type calcium channel complex at a presynaptic nerve
terminal: analysis by quantitative immunocolocalization. J Neurosci 24:
4070 – 4081
61. Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S (2004)
Automatic and quantitative measurement of protein-protein colocaliza-
tion in live cells. Biophys J 86: 3993 – 4003
62. Tsafrir D, Tsafrir I, Ein-Dor L, Zuk O, Notterman DA, Domany E (2005)
Sorting points into neighborhoods (SPIN): data analysis and visualiza-
tion by ordering distance matrices. Bioinformatics 21: 2301 – 2308
63. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A,
Blandino G, Piaggio G (2006) Gain of function of mutant p53: the
mutant p53/NF-Y protein complex reveals an aberrant transcriptional
mechanism of cell cycle regulation. Cancer Cell 10: 191 – 202
64. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S,
Fauron C, He X, Hu Z et al (2009) Supervised risk predictor of breast
cancer based on intrinsic subtypes. J Clin Oncol 27: 1160 – 1167
65. Gendoo DM, Ratanasirigulchai N, Schroder MS, Pare L, Parker JS, Prat A,
Haibe-Kains B (2015) Genefu: an R/Bioconductor package for computa-
tion of gene expression-based signatures in breast cancer. Bioinformatics
32: 1097 – 1099
EMBO reports ª 2017 The Authors
EMBO reports lncRNA MALAT1 inhibits anti-angiogenic VEGFAxxxb expression Magdalena Pruszko et al
20
Published online: June 26, 2017 
66. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed
D, Lynch AG, Samarajiwa S, Yuan Y et al (2012) The genomic and tran-
scriptomic architecture of 2,000 breast tumours reveals novel
subgroups. Nature 486: 346 – 352
67. Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako
T, Quigley DA, Kristensen VN, Aparicio S, Borresen-Dale AL et al
(2014) TP53 mutation spectrum in breast cancer is subtype specific
and has distinct prognostic relevance. Clin Cancer Res 20:
3569 – 3580
68. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang
H, McLellan M, Yau C, Kandoth C et al (2015) Comprehensive molecular
portraits of invasive lobular breast cancer. Cell 163: 506 – 519
ª 2017 The Authors EMBO reports
Magdalena Pruszko et al lncRNA MALAT1 inhibits anti-angiogenic VEGFAxxxb expression EMBO reports
21
Published online: June 26, 2017 
